In pancreatic cancer patients receiving FOLFIRINOX, tumor size reduction significantly increased resectability and pathologic response. Normalization of carbohydrate antigen 19-9 levels predicted resectability, lower recurrence risk, and improved survival. Postoperative antigen 19-9 rise, following prior normalization after neoadjuvant therapy, signaled heightened recurrence risk and poorer survival. Tailoring treatment response assessments can guide personalized strategies for pancreatic ductal adenocarcinoma management.
Journal Article by Servin-Rojas M, Fong ZV (…) Qadan M et 7 al. in BMC Surg
Copyright © 2023 Elsevier Inc. All rights reserved.